eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | multiple myeloma |
| Symptom | C0005940|bone disease |
| Sentences | 33 |
| PubMedID- 20572008 | Our group has examined their role in the progression of the osteolytic bone disease associated with multiple myeloma. |
| PubMedID- 24381787 | Diagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvement. |
| PubMedID- 24074513 | Objectives: bone disease is one of the hallmarks of multiple myeloma (mm). |
| PubMedID- 23416846 | No anabolic drugs are currently approved to treat multiple myeloma (mm)-induced bone disease and the anti-mm agent bortezomib exhibits the anabolic effects in the clinic. |
| PubMedID- 24656650 | Bone marrow plasma macrophage inflammatory protein protein-1 alpha(mip-1 alpha) and sclerostin in multiple myeloma: relationship with bone disease and clinical characteristics. |
| PubMedID- 22902442 | bone disease associated with multiple myeloma(mm)is characterized by increased osteoclast activity and suppressed osteoclast function because of some factors produced by myeloma cells, leading to severe osteolytic lesions. |
| PubMedID- 21411443 | Osteolytic bone disease is pathognomonic of multiple myeloma (mm) and affects more than 80% of patients. |
| PubMedID- 21732484 | multiple myeloma is closely associated with induction of bone disease and large lytic lesions, which are often not repaired and are usually the sites of relapses. |
| PubMedID- 21745013 | bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management. |
| PubMedID- 24433088 | Management of bone disease in multiple myeloma. |
| PubMedID- 25491781 | Diagnosis of mm is made based on the clonal plasmacytosis of at least 15% on bone marrow examination or biopsy-proven clonal plasmacytoma, the presence of m protein in serum or urine, and any evidence of end-organ damage (i.e., hypercalcemia, renal insufficiency, anemia, and bone disease) attributable to myeloma involvement 7. |
| PubMedID- 24422114 | Thus, bortezomib is recommended for myeloma patients with extended bone disease in combination with bisphosphonates. |
| PubMedID- 23431957 | Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease. |
| PubMedID- 22952578 | This agent has been in development for the treatment of osteolytic bone disease in patients with multiple myeloma, for the treatment of bone disease in bone metastases and for osteoporosis in post- menopausal women , , . |
| PubMedID- 21569702 | Objective: to explore the difference of effects of two regimens (bortezomib and dexamethasone, bd; and thalidomide and dexamethasone, td) on bone disease in multiple myeloma (mm). |
| PubMedID- 22454220 | Zoledronic acid (zol), an intravenous bisphosphonate, has been shown to reduce and delay the incidence of skeletal-related events (sres) in multiple myeloma (mm) patients with bone disease. |
| PubMedID- 26579531 | bone disease, the hallmark of multiple myeloma (mm), is characterized by the presence of pure lytic lesions instead of solid tumors . |
| PubMedID- 21649546 | Traditionally, the skeletal survey has been the standard modality for the detection of osteolytic bone disease in multiple myeloma. |
| PubMedID- 25187738 | bone disease in multiple myeloma: pathophysiology and management. |
| PubMedID- 20664052 | Osteoclast (oc)-mediated lytic bone disease remains a cause of major morbidity in multiple myeloma. |
| PubMedID- 25628928 | Osteolytic bone disease in multiple myeloma (mm) is associated with upregulated osteoclast activity. |
| PubMedID- 23931337 | Serum c terminal telopeptide maintains its correlation with bone disease in patients with myeloma even under treatment with bisphosphonates. |
| PubMedID- 20722619 | For over 2 decades bisphosphonates have been successfully used to treat the tumour-induced bone disease associated with multiple myeloma. |
| PubMedID- 24164102 | Zoledronic acid (zol) is frequently used for the treatment of bone disease in patients with multiple myeloma and breast cancer with metastasis to bone. |
| PubMedID- 26345558 | Management of bone disease in myeloma patients: zoledronic acid or denosumab. |
| PubMedID- 22498739 | Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the medical research council myeloma ix trial. |
| PubMedID- 23417027 | Given the prevalence of osteolytic bone disease in multiple myeloma (mm), novel therapies targeting bone microenvironment are essential. |
| PubMedID- 24249482 | The effects of bortezomib on bone disease in patients with multiple myeloma. |
| PubMedID- 22726547 | bone disease in patients with multiple myeloma (mm) is characterized by increase in the numbers and activity of bone-resorpting osteoclasts and decrease in the number and function of bone-formation osteoblasts. |
| PubMedID- 21991938 | Osteolytic bone disease is a hallmark of symptomatic multiple myeloma. |
| PubMedID- 20863761 | Interpretation: monthly infusion of pamidronate 30 mg should be the recommended dose for prevention of bone disease in patients with multiple myeloma. |
| PubMedID- 21403648 | myeloma patients with extensive bone disease have high serum levels of ccl3 (21). |
| PubMedID- 25626302 | Osteolytic bone disease in multiple myeloma (mm) affects more than 80% of patients. |
Page: 1